APA (7th ed.) Citation

Wagle, N., Grabiner, B. C., Van Allen, E. M., Hodis, E., Jacobus, S., Supko, J. G., . . . Rosenberg, J. E. (2014). Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer discovery, 4(5), 546-553. https://doi.org/10.1158/2159-8290.CD-13-0353

Chicago Style (17th ed.) Citation

Wagle, Nikhil, et al. "Activating MTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib." Cancer Discovery 4, no. 5 (2014): 546-553. https://doi.org/10.1158/2159-8290.CD-13-0353.

MLA (9th ed.) Citation

Wagle, Nikhil, et al. "Activating MTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib." Cancer Discovery, vol. 4, no. 5, 2014, pp. 546-553, https://doi.org/10.1158/2159-8290.CD-13-0353.